Abstract: A blood pressure measurement device includes: a case including an outer case, a base housed in the outer case, and a back cover that covers an opening of the outer case; a movable portion arranged in a gap between the outer case, the base and the back cover, and including a bag-shaped cuff that inflates when a fluid is supplied to an internal space; and a seal member that is formed of a gel body having a lower elastic modulus than that of the cuff, and that is provided in the gap to seal the gap.

Abstract: A coin cell battery includes a sealing plate having one polarity and a battery can having another polarity. A mark of a letter, a number, a symbol, a shape, a color, or a combination thereof is formed on an outer surface of at least of the sealing plate and the battery can. The mark is made of a layer containing an aversive agent.

Abstract: A process for preparing optically active 3-hydroxy-.gamma.-butyrolactone or optically active 3-hydroxytetrahydrofuran through a short route and by using an easily available and inexpensive starting material and an inexpensive reagent easy to handle is disclosed. The process comprises cyclizing an optically active compound represented by formula (II): ##STR1## wherein Q represents an alkoxycarbonyl group having 1 to 4 carbon atoms or a hydroxymethyl group; X represents a halogen atom; and the asterisk * means an asymmetric carbon atom, under an acidic condition.

Abstract: Disclosed herein is a process for producing a (2S,5S)-2,5-diamino-1,6-diphenyl-3-hexanone derivative represented by the formula (1): ##STR1## wherein R.sup.1 means a lower alkylcarbonyl group, a halogen-substituted lower alkylcarbonyl group, an arylcarbonyl group or a lower alkoxycarbonyl group, and R.sup.2 and R.sup.3 are identical with or different from each other and denote individually an aryl group or an alkoxy-substituted aryl group, which comprises subjecting a (2S)-2,5-diamino-1,6-diphenyl-4-hexen-3-one derivative represented by the formula (2): ##STR2## wherein R.sup.1, R.sup.2 and R.sup.3 have the same meaning as defined above, to a hydrogenation reaction in the presence of a transition metal-containing catalyst.

Abstract: Disclosed herein is a process for producing a (2S,5S)-2,5-diamino-1,6-diphenyl-3-hexanone derivative represented by the formula (1): ##STR1## wherein R.sup.1 means a lower alkylcarbonyl group, a halogen-substituted lower alkylcarbonyl group, an arylcarbonyl group or a lower alkoxycarbonyl group, and R.sup.2 and R.sup.3 are identical with or different from each other and denote individually an aryl group or an alkoxy-substituted aryl group, which comprises subjecting a (2S)-2,5-diamino-1,6-diphenyl-4-hexen-3-one derivative represented by the formula (2): ##STR2## wherein R.sup.1, R.sup.2 and R.sup.3 have the same meaning as defined above, to a hydrogenation reaction in the presence of a transition metal-containing catalyst.

Abstract: A process for for producing a (2R,3S)-cyclohexylnorstatine or a salt thereof is disclosed, which comprises the steps of: enantioselectively hydrogenating a 4-cyclohexyl-2-halogeno-3-oxobutyric acid ester in the presence of a ruthenium-phosphine complex to produce a 4-cyclohexyl-2-halogeno-(3R)-hydroxybutyric acid ester (2); epoxidizing the compound (2) in the presence of a base to produce a 4-cyclohexyl-(2S,3R)-epoxybutyric acid ester (3); reacting the compound (3) with a lower trialkylsilyl azide in the presence of a Lewis acid to produce a (3S)-azide-4-cyclohexyl-(2S)-substituted butyric acid ester (4); subjecting the compound (4) to hydrogenolysis to produce a (2S,3S)-cyclohexylnorstatine derivative (5); and inverting the configuration at the 2-position of the compound (5).

Abstract: A process for for producing a (2R,3S)-cyclohexylnorstatine or a salt thereof is disclosed, which comprises the steps of: enantioselectively hydrogenating a 4-cyclohexyl-2-halogeno-3-oxobutyric acid ester in the presence of a ruthenium-phosphine complex to produce a 4-cyclohexyl-2-halogeno-(3R)-hydroxybutyric acid ester (2); epoxidizing the compound (2) in the presence of a base to produce a 4-cyclohexyl-(2S,3R)-epoxybutyric acid ester (3); reacting the compound (3) with a lower trialkylsilyl azide in the presence of a Lewis acid to produce a (3S)-azide-4-cyclohexyl-(2S)-substituted butyric acid ester (4); subjecting the compound (4) to hydrogenolysis to produce a (2S,3S)-cyclohexylnorstatine derivative (5); and inverting the configuration at the 2-position of the compound (5).

Abstract: A process for producing an optically active 1-substituted-1,3-propanediol is disclosed, comprising hydrogenating a 3-substituted-3-oxopropanol or 3-substituted-3-oxopropanal in the presence of a ruthenium-phosphine complex represented by formula (I):[RuI(p-cymene)(R.sup.1 BINAP)]I.sub.3 (I)wherein R.sup.1 -BINAP represents an optically active tertiary phosphine represented by formula (II): ##STR1## wherein R.sup.1 represents a phenyl group which may be substituted with a lower alkyl group or a halogen atom at the p-position and/or m-position.

Abstract: A ruthenium-phosphine complex is disclosed, represented by formula (I):[RuI(p-cymene)(R.sup.1 -BINAP)]I.sub.3 (I)where R.sup.1 -BINAP represents a tertiary phosphine represented by formula (II): ##STR1## wherein R.sup.1 represents a phenyl group which may be substituted with a lower alkyl group or a halogen atom at the p-position and/or m-position. A process for producing an optically active 1-substituted-1,3-propanediol is also disclosed, comprising hydrogenating a 3-substituted-3-oxopropanol or 3-substituted-3-oxopropanal in the presence of the ruthenium-phosphine complex of formula (I).